Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 6, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025.
Read more at globenewswire.com
